Uveal melanoma secondary prevention: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
Currently, there is no consensus regarding type or frequency of scans following diagnosis and treatment of the primary eye tumor. Approximately half of the patients with uveal melanoma will develop metastases within 15 years of initial diagnosis. Approximately 2% patients would show an evidence of metastasis at the time of initial uveal melanoma diagnosis. Of the 50% of patients who develop metastatic disease, more than 90% of patients will develop liver metastases. As such, the majority of surveillance techniques are focused on the liver. The surveillance techniques include regular dilated [[fundus]] examination, abdominal [[magnetic resonance imaging]] (MRI), abdominal [[ultrasound]] and [[liver function tests]]. These surveillance tests are performed every 6-12 months and can continue for many years. | Currently, there is no consensus regarding type or frequency of scans following diagnosis and treatment of the primary eye tumor. Approximately half of the patients with uveal melanoma will develop metastases within 15 years of initial diagnosis. Approximately 2% patients would show an evidence of metastasis at the time of initial uveal melanoma diagnosis. Of the 50% of patients who develop metastatic disease, more than 90% of patients will develop liver metastases. As such, the majority of surveillance techniques are focused on the liver. The surveillance techniques include regular dilated [[fundus]] examination, abdominal [[magnetic resonance imaging]] (MRI), abdominal [[ultrasound]] and [[liver function tests]]. These surveillance tests are performed every 6-12 months and can continue for many years. | ||
== References == | == References == | ||
{{ | |||
{{reflist|2}} | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Disease]] | |||
[[Category:Ophthalmology]] | |||
Revision as of 14:11, 28 October 2015
|
Uveal melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Uveal melanoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Uveal melanoma secondary prevention |
|
Risk calculators and risk factors for Uveal melanoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Secondary prevention strategies following uveal melanoma include dilated fundus examination, liver function tests, abdominal MRI and abdominal ultrasound.
Secondary Prevention
Currently, there is no consensus regarding type or frequency of scans following diagnosis and treatment of the primary eye tumor. Approximately half of the patients with uveal melanoma will develop metastases within 15 years of initial diagnosis. Approximately 2% patients would show an evidence of metastasis at the time of initial uveal melanoma diagnosis. Of the 50% of patients who develop metastatic disease, more than 90% of patients will develop liver metastases. As such, the majority of surveillance techniques are focused on the liver. The surveillance techniques include regular dilated fundus examination, abdominal magnetic resonance imaging (MRI), abdominal ultrasound and liver function tests. These surveillance tests are performed every 6-12 months and can continue for many years.